GlassScriptPhysician profile
Matthew Norton
NPI 1205064870
$3,012.17
in general payments reported to CMS, 2019-2025
32 companies · $985 in 2025
The $985 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.15 · 2020: $46.20 · 2021: $98.76 · 2022: $460 · 2023: $458 · 2024: $952 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $541.39 | 2021-2025 | |
| Novo Nordisk INC | $525.99 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $356.37 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $226.78 | 2023-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.39 | 2022-2025 | Jardiance |
| Amgen INC. | $217.82 | 2023-2025 | Evenity, Repatha, Prolia |
| Abbott Laboratories | $107.52 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $89.75 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $86.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $64.54 | 2023-2025 | |
| Lundbeck LLC | $62.33 | 2024-2025 | Rexulti |
| Dexcom, INC. | $45.59 | 2022-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $45.15 | 2024-2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.18 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $35.48 | 2022-2025 | Trintellix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $35.21 | 2025 | Omnipod |
| Edwards Lifesciences Corporation | $35.15 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Ibsa Pharma INC. | $31.04 | 2022-2024 | Tirosint, Licart |
| Rgh Enterprises LLC | $27.54 | 2025 | |
| Genentech USA, INC. | $24.62 | 2024 | Xolair |
| Mylan Specialty L.P. | $20.24 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $19.01 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Vbi Vaccine (Delaware) INC. | $18.89 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.06 | 2025 | Qelbree |
| Novartis Pharmaceuticals Corporation | $17.47 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.33 | 2024 | |
| Terumo Medical Corporation | $15.20 | 2025 | Azur Cx Detachable |
| Allergan, INC. | $14.78 | 2020 | |
| Almatica Pharma LLC | $14.13 | 2024 | Loreev Xr |
| Nabriva Therapeutics, Plc | $13.95 | 2020 | |
| Boston Scientific Corporation | $13.66 | 2025 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Norton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.